Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T20:52:19.554Z.
Consensus retrieved: 2026-10-06T13:54:15.394Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:52:19.554Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c401c00e52a09452fdcb188d3872e1091efc1230c6c65f2aa9c0ebb48d3df0bd
Forward PE Ratio (N/A) = Dated Quote Price ($3.64) / Consensus Forward EPS ($-1.76)
FORWARD PE RATIO
N/A
MacroGenics, Inc.
Market Cap
$231.37M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| MacroGenics, Inc. (MGNX) | $231.37M | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $231.77M | N/A |
| InflaRx N.V. (IFRX)vs › | $232.72M | N/A |
| Vogenx Inc. (VOGX)vs › | $227.91M | N/A |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | N/A |
| Biodesix, Inc. (BDSX)vs › | $227.60M | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.66M | N/A |
| SIGA Technologies, Inc. (SIGA)vs › | $235.97M | 1.94 |
| BioAge Labs Inc. (BIOA)vs › | $236.82M | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $3.64, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.76 | $-2.62 – $-0.91 | 5 | n/m |
| 2027-12-31 | $-1.64 | $-2.23 – $-1.05 | 3 | n/m |
| 2028-12-31 | $-2.05 | $-3.35 – $-1.43 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
